Furthermore, administration of the IFN-β-secreting human MSCs into tongue squamous cell carcinoma (TSCC) (94), and also glioma xenografts (95) exerted dramatic antitumor responses in vivo. This evidence concerns the gene IFNB1 and central nervous system cancer.